The stock of Evogene Ltd (EVGN) has gone down by -14.40% for the week, with a -21.90% drop in the past month and a -64.33% drop in the past quarter. The volatility ratio for the week is 10.96%, and the volatility levels for the past 30 days are 10.26% for EVGN. The simple moving average for the past 20 days is -19.92% for EVGN’s stock, with a -65.78% simple moving average for the past 200 days.
Is It Worth Investing in Evogene Ltd (NASDAQ: EVGN) Right Now?
Additionally, the 36-month beta value for EVGN is 1.40. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EVGN is 4.97M and currently, short sellers hold a 0.29% ratio of that float. The average trading volume of EVGN on October 18, 2024 was 28.90K shares.
EVGN) stock’s latest price update
The stock of Evogene Ltd (NASDAQ: EVGN) has decreased by -16.08 when compared to last closing price of 2.55.Despite this, the company has seen a loss of -14.40% in its stock price over the last five trading days. prnewswire.com reported 2024-10-08 that Following a successful first year, Israel Innovation Authority (IIA) approved financing second year of collaboration HAZEVA and REHOVOT, Israel, Oct. 8, 2024 /PRNewswire/ — Watershed AC (“Watershed”, formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd.
Analysts’ Opinion of EVGN
Many brokerage firms have already submitted their reports for EVGN stocks, with ROTH Capital repeating the rating for EVGN by listing it as a “Buy.” The predicted price for EVGN in the upcoming period, according to ROTH Capital is $7 based on the research report published on October 08, 2021 of the previous year 2021.
Aegis Capital, on the other hand, stated in their research note that they expect to see EVGN reach a price target of $10. The rating they have provided for EVGN stocks is “Buy” according to the report published on July 29th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to EVGN, setting the target price at $9 in the report published on December 01st of the previous year.
EVGN Trading at -31.87% from the 50-Day Moving Average
After a stumble in the market that brought EVGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.42% of loss for the given period.
Volatility was left at 10.26%, however, over the last 30 days, the volatility rate increased by 10.96%, as shares sank -20.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.65% lower at present.
During the last 5 trading sessions, EVGN fell by -14.40%, which changed the moving average for the period of 200-days by -75.43% in comparison to the 20-day moving average, which settled at $2.67. In addition, Evogene Ltd saw -74.52% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for EVGN
Current profitability levels for the company are sitting at:
- -2.33 for the present operating margin
- 0.68 for the gross margin
The net margin for Evogene Ltd stands at -2.1. The total capital return value is set at -0.63. Equity return is now at value -228.95, with -42.13 for asset returns.
Based on Evogene Ltd (EVGN), the company’s capital structure generated 0.79 points at debt to capital in total, while cash flow to debt ratio is standing at -1.74. The debt to equity ratio resting at 3.65. The interest coverage ratio of the stock is 57.58.
Currently, EBITDA for the company is -23.78 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 0.3. The receivables turnover for the company is 25.13for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.37.
Conclusion
In conclusion, Evogene Ltd (EVGN) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
